{"id":"NCT00371137","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Safety and Efficacy Study of Xyrem速 in Subjects With Fibromyalgia","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem速 in Subjects With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-09","completion":"2008-12","firstPosted":"2006-09-01","resultsPosted":"2011-11-30","lastUpdate":"2011-12-29"},"enrollment":548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Xyrem速","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The objective of this trial is to evaluate the safety and efficacy of Xyrem速 compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.","primaryOutcome":{"measure":"Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).","timeFrame":"Baseline to Week 14","effectByArm":[{"arm":"Placebo","deltaMin":27.3,"sd":null},{"arm":"Xyrem 4.5g","deltaMin":46.2,"sd":null},{"arm":"Xyrem 6.0g","deltaMin":39.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":">0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":70,"countries":["United States"]},"refs":{"pmids":["21397402","19116896"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":183},"commonTop":["Headache","Nausea","Dizziness","Vomiting","Diarrhoea"]}}